Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

JAMA Netw Open. 2026 May 1;9(5):e2614557. doi: 10.1001/jamanetworkopen.2026.14557.
No abstract available

Plain language summary

This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.